Who
John Neis
Director
Company insider
Files Form 4 as: Director, Cellectar Biosciences; Director and 10% owner, TomoTherapy; Director, Third Wave Technologies Inc /wi.
In numbers
- Trades disclosed
- 38
- Buys
- 3
- Sells
- 5
- Bought
- $2.0M
- Sold
- $67.5M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 9 Jan 2006
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Sold | $733198 at $3.70 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 28 Jun 2023filed 28 Jun 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 24 Jun 2022filed 1 Aug 2022 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 30 Jun 2021filed 2 Jul 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,000 at $0.00 | filing |
| 18 Mar 2021filed 19 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code S | $5,80823,232 at $0.25 | filing |
| 17 Mar 2021filed 19 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code S | $16K58,640 at $0.28 | filing |
| 16 Mar 2021filed 16 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code S | $31K100,515 at $0.31 | filing |
| 15 Mar 2021filed 16 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code S | $3,02411,200 at $0.27 | filing |
| 12 Mar 2021filed 16 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code S | $11K41,155 at $0.27 | filing |
| 24 Jun 2020filed 25 Jun 2020 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 13 Jun 2019filed 14 Jun 2019 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 12 Oct 2018filed 15 Oct 2018 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 14 Nov 2017filed 16 Nov 2017 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Sold | $7,7695,214 at $1.49 | filing |
| 31 May 2017filed 1 Jun 2017 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 29 Nov 2016filed 30 Nov 2016 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $497K333,333 at $1.49 | filing |
| 29 Nov 2016filed 30 Nov 2016 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $3,333333,333 at $0.01 | filing |
News
Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström PatientsCLRB · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name John Neis; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.